TY - JOUR
T1 - Outcomes of oocyte vitrification in trans masculine individuals
AU - Asseler, Joyce D.
AU - Knieriem, Julie
AU - Huirne, Judith A. F.
AU - Goddijn, Mariette
AU - Verhoeven, Marieke O.
AU - van Mello, Norah M.
N1 - Funding Information: The authors especially want to thank all patients for their participation in the study. JA and NM conceived and designed the study. JA and JK contributed to acquisition of the data. JA contributed to the analysis and JA, JH, MG, MV and NM contributed to the interpretation of the data. All authors made contributions to drafting and revising the article critically for important intellectual content. All authors approved the final version of the article to be published. MG and MV declare that their department (reproductive medicine) received research and educational grants from Guerbet, Merck and Ferring (all location VUmc), outside the scope of the submitted work. JH received grants from ZonMw, Samsung and PlantTec MedicalGmbH outside the scope of the submitted work. Publisher Copyright: © 2023 The Authors
PY - 2023/7
Y1 - 2023/7
N2 - Research question: What are the outcomes and experiences of oocyte vitrification treatment in trans masculine individuals (TMI) before and after testosterone use? Design: This retrospective cohort study was conducted at the Amsterdam UMC in the Netherlands between January 2017 and June 2021. The TMI who had completed an oocyte vitrification treatment were consecutively approached for participation. Informed consent was provided by 24 individuals. Participants (n = 7) who initiated testosterone therapy were advised to stop 3 months before stimulation. Demographic characteristics and oocyte vitrification treatment data were retrieved from medical records. Evaluation of the treatment was collected via an online questionnaire. Results: The median age of participants was 22.3 years (interquartile range 21.1–26.0) and mean body mass index was 23.0 kg/m2 (SD 3.2). After ovarian hyperstimulation, a mean of 20 oocytes (SD 7) were retrieved and a mean of 17 oocytes (SD 6) could be vitrified. Aside from a lower cumulative FSH dose, there were no significant differences between the prior testosterone users and testosterone naïve TMI. The overall satisfaction of oocyte vitrification treatment in participants was high. Hormone injections were considered the most strenuous part of treatment by 29% of participants, closely followed by oocyte retrieval (25%). Conclusions: No difference in response to ovarian stimulation was found for oocyte vitrification treatment between the prior testosterone users and testosterone naïve TMI. The questionnaire identified hormone injections as the most burdensome aspect of oocyte vitrification treatment. This information can be used to improve gender sensitive fertility counselling and fertility treatment strategies.
AB - Research question: What are the outcomes and experiences of oocyte vitrification treatment in trans masculine individuals (TMI) before and after testosterone use? Design: This retrospective cohort study was conducted at the Amsterdam UMC in the Netherlands between January 2017 and June 2021. The TMI who had completed an oocyte vitrification treatment were consecutively approached for participation. Informed consent was provided by 24 individuals. Participants (n = 7) who initiated testosterone therapy were advised to stop 3 months before stimulation. Demographic characteristics and oocyte vitrification treatment data were retrieved from medical records. Evaluation of the treatment was collected via an online questionnaire. Results: The median age of participants was 22.3 years (interquartile range 21.1–26.0) and mean body mass index was 23.0 kg/m2 (SD 3.2). After ovarian hyperstimulation, a mean of 20 oocytes (SD 7) were retrieved and a mean of 17 oocytes (SD 6) could be vitrified. Aside from a lower cumulative FSH dose, there were no significant differences between the prior testosterone users and testosterone naïve TMI. The overall satisfaction of oocyte vitrification treatment in participants was high. Hormone injections were considered the most strenuous part of treatment by 29% of participants, closely followed by oocyte retrieval (25%). Conclusions: No difference in response to ovarian stimulation was found for oocyte vitrification treatment between the prior testosterone users and testosterone naïve TMI. The questionnaire identified hormone injections as the most burdensome aspect of oocyte vitrification treatment. This information can be used to improve gender sensitive fertility counselling and fertility treatment strategies.
KW - OHSS
KW - cryopreservation
KW - fertility preservation
KW - oocyte vitrification
KW - transgender
UR - http://www.scopus.com/inward/record.url?scp=85153310447&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.rbmo.2023.03.007
DO - https://doi.org/10.1016/j.rbmo.2023.03.007
M3 - Article
C2 - 37095040
SN - 1472-6483
VL - 47
SP - 94
EP - 101
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 1
ER -